MedTrace Logo

HCC Staging Modified by Tumor Micronecrosis

NCT05739110 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1100

Last updated 2023-02-22

No results posted yet for this study

Summary

Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic significance of tumor micronecrosis based on the current BCLC and TNM staging systems, and futher improve the performance of the staging models by establishing modified new staging models including tumor micronecrosis.

Conditions

Interventions

BEHAVIORAL

tumor micronecrosis

whether HCC patients have tumor micronecrosis or not

Sponsors & Collaborators

  • Huizhou Municipal Central Hospital

    collaborator OTHER

  • Second Affiliated Hospital of Nanchang University

    collaborator OTHER

  • Meng Chao Hepatobiliary Hospital of Fujian Medical University

    collaborator OTHER

  • Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2022-12-01
Completion
2023-01-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05739110 on ClinicalTrials.gov